Kazia Therapeutics (KZIA) Debt to Equity (2011 - 2025)

Kazia Therapeutics has reported Debt to Equity for 6 years, with the latest figure at $0.31 in Q4 2025.

• For the quarter ending Q4 2025, Debt to Equity changed N/A year-over-year to $0.31; the trailing twelve-month figure through Dec 2025 stood at $0.31 (changed N/A YoY), and the FY2025 full-year result was -$0.38, up 41.32% from the prior year.
• Debt to Equity for Q4 2025 stood at $0.31, up from -$0.38 in the prior quarter.
• The five-year high for Debt to Equity was $1.63 in Q4 2023, with the low at -$0.65 in Q2 2024.
• Historically, Debt to Equity has averaged $0.25 across 4 years, with a median of $0.1 in 2022.
• Annual changes were most pronounced in 2023 — Debt to Equity jumped 808.34% — and 2024, when it tumbled 190.62%.
• Kazia Therapeutics' Debt to Equity stood at -$0.1 in 2022, then jumped by 1720.56% to $1.63 in 2023, then slumped by 139.61% to -$0.65 in 2024, then surged by 147.19% to $0.31 in 2025.
• The last three Debt to Equity figures came in at $0.31 (Q4 2025), -$0.38 (Q2 2025), and -$0.65 (Q2 2024), per Business Quant data.